Compass Therapeutics (CMPX) Competitors $3.00 -0.15 (-4.76%) Closing price 04:00 PM EasternExtended Trading$3.01 +0.01 (+0.20%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPX vs. JANX, BHVN, ANIP, MESO, EWTX, TVTX, CVAC, PAHC, ABCL, and CALTShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include Janux Therapeutics (JANX), Biohaven (BHVN), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Travere Therapeutics (TVTX), CureVac (CVAC), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), and Calliditas Therapeutics AB (publ) (CALT). These companies are all part of the "pharmaceutical products" industry. Compass Therapeutics vs. Its Competitors Janux Therapeutics Biohaven ANI Pharmaceuticals Mesoblast Edgewise Therapeutics Travere Therapeutics CureVac Phibro Animal Health AbCellera Biologics Calliditas Therapeutics AB (publ) Compass Therapeutics (NASDAQ:CMPX) and Janux Therapeutics (NASDAQ:JANX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation. Is CMPX or JANX more profitable? Janux Therapeutics' return on equity of -9.29% beat Compass Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Compass TherapeuticsN/A -42.47% -38.31% Janux Therapeutics N/A -9.29%-8.89% Does the media favor CMPX or JANX? In the previous week, Janux Therapeutics had 4 more articles in the media than Compass Therapeutics. MarketBeat recorded 5 mentions for Janux Therapeutics and 1 mentions for Compass Therapeutics. Compass Therapeutics' average media sentiment score of 1.18 beat Janux Therapeutics' score of 0.42 indicating that Compass Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Compass Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, CMPX or JANX? Compass Therapeutics has higher earnings, but lower revenue than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Compass Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCompass Therapeutics$850K488.05-$49.38M-$0.41-7.32Janux Therapeutics$10.59M147.51-$68.99M-$1.36-19.41 Do analysts rate CMPX or JANX? Compass Therapeutics presently has a consensus price target of $12.67, suggesting a potential upside of 322.22%. Janux Therapeutics has a consensus price target of $91.89, suggesting a potential upside of 248.06%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Compass Therapeutics is more favorable than Janux Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Janux Therapeutics 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.08 Which has more volatility and risk, CMPX or JANX? Compass Therapeutics has a beta of 1.48, meaning that its share price is 48% more volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 2.86, meaning that its share price is 186% more volatile than the S&P 500. Do institutionals and insiders hold more shares of CMPX or JANX? 68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are owned by institutional investors. 29.8% of Compass Therapeutics shares are owned by company insiders. Comparatively, 8.1% of Janux Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryCompass Therapeutics and Janux Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$435.59M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E RatioN/A8.2821.0120.09Price / Sales488.05303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book3.307.678.125.65Net Income-$49.38M-$55.28M$3.25B$257.91M7 Day Performance11.11%2.50%0.97%2.09%1 Month Performance26.05%11.70%7.36%11.13%1 Year Performance212.50%4.89%31.31%18.40% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics2.9321 of 5 stars$3.00-4.8%$12.67+322.2%+205.8%$435.59M$850K0.0020Positive NewsJANXJanux Therapeutics2.0145 of 5 stars$23.96-2.0%$95.25+297.5%-36.8%$1.42B$10.59M-17.6230News CoverageBHVNBiohaven3.3597 of 5 stars$13.81-5.6%$58.46+323.3%-58.2%$1.41BN/A-1.48239Trending NewsANIPANI Pharmaceuticals3.7657 of 5 stars$64.91-0.6%$80.13+23.4%+8.0%$1.41B$614.38M-51.11600MESOMesoblast1.6926 of 5 stars$10.53-1.4%$18.00+70.9%+67.2%$1.35B$5.90M0.0080News CoveragePositive NewsAnalyst DowngradeGap UpEWTXEdgewise Therapeutics1.4953 of 5 stars$12.61-3.2%$40.00+217.2%-36.1%$1.33BN/A-8.1460TVTXTravere Therapeutics3.7272 of 5 stars$14.60-2.7%$32.14+120.2%+60.4%$1.30B$273.53M-5.20460News CoverageAnalyst RevisionCVACCureVac4.7525 of 5 stars$5.41-0.7%$6.83+26.3%+47.9%$1.21B$523.70M5.88880Positive NewsPAHCPhibro Animal Health4.0498 of 5 stars$29.90+6.8%$24.40-18.4%+56.3%$1.21B$1.02B38.331,940News CoverageHigh Trading VolumeABCLAbCellera Biologics2.3189 of 5 stars$4.03+6.1%$7.50+86.1%+15.7%$1.20B$28.83M-7.20500High Trading VolumeCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180 Related Companies and Tools Related Companies JANX Alternatives BHVN Alternatives ANIP Alternatives MESO Alternatives EWTX Alternatives TVTX Alternatives CVAC Alternatives PAHC Alternatives ABCL Alternatives CALT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPX Stock Alerts